Styrelsen i XVIVO Perfusion AB (publ) (”XVIVO”) har utsett Christoffer Rosenblad till VD. Christoffer har varit tillförordnad VD sedan 27 september, 2022 och han tillträder nu rollen som VD med omedelbar verkan.
Read moreThe board of XVIVO Perfusion AB (publ) (“XVIVO”) has appointed Christoffer Rosenblad as CEO. Christoffer has had the role of acting CEO since September 27, 2022 and will take up his permanent role immediately.
Read moreXVIVO continues to build and strengthen the company. XVIVO has a firm strategy plan for the coming five years, and as part of securing the company’s global market leading position Lena Hagman has been appointed COO.
Read moreXVIVO fortsätter att bygga och stärka företaget. XVIVO har en tydlig strategi för de kommande fem åren och som ett led i att säkra företagets globala marknadsledande position har Lena Hagman utsetts till COO.
Read moreTo successfully execute on XVIVO’s strategy, Fredrik Dalborg has been appointed Managing Director North America and will become a member of the XVIVO executive management team. North America is XVIVO’s most important region where XVIVO anticipate strong growth over the next few years, and also to become market leader in all major organs. Fredrik will lead the full North America commercial team and be responsible for the overall US operations.
Read more
